When was Auron Therapeutics founded?

Auron Therapeutics was founded in 2018 and raised its 1st funding round 2 years after it was founded.

Where is Auron Therapeutics located?

Auron Therapeutics is headquartered in Wellesley, United States.

Who is the current CEO of Auron Therapeutics?

Kate Yen of Auron Therapeutics. They have also founded 1 company.

How many employees does Auron Therapeutics have?

As of Mar 31, 2026, the latest employee count at Auron Therapeutics is 23.

Is Auron Therapeutics a funded company?

Auron Therapeutics is a funded company, having raised a total of $118M across 4 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Dec 16, 2020.

When was the latest funding round of Auron Therapeutics?

Auron Therapeutics' latest funding was a $***** Series B round on Feb 04, 2025, with participation from 9 investors. Its primary sector is Oncology. In United States, the Oncology sector has seen $1.41B in funding in 2026 to date.

Where does Auron Therapeutics rank among its competitors?

Auron Therapeutics ranks 20th amongst 443 active competitors, of which 169 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Evommune, which secured $125M in Feb, 2026.

Who are the top competitors of Auron Therapeutics?

Auron Therapeutics' top competitors include Septerna, Philogen and Escient Pharmaceuticals. Among them, Evommune secured the most recent funding round in February, 2026.

Auron Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of cancer therapeutics for the treatment of blood cancer. The company has developed its proprietary differentiation therapy used for the treatment of hematologic malignancies. It helps in reactivating endogenous cellular programs to elicit tumor cell maturation and reprogram cancer tissue to a normal phenotype. It can be used to treat acute promyelocytic leukemia (APL) by differentiating malignant promyelocytes into non-cancerous cell neutrophils.

Website: www.aurontx.com/
Email ID: *****@aurontx.com

Key Metrics

Founded Year

2018

Location

Wellesley, United States

Stage

Series B

Total Funding

$118M in 4 rounds

Latest Funding Round

Series B, Feb 04, 2025, $*****

Investors

Polaris Partners & 12 more

Ranked

20^th among 443 active competitors

Employee Count

23 as on Mar 31, 2026

Similar Companies

Septerna & 508 more

View Auron Therapeutics' full profile

Auron Therapeutics has raised a total funding of $118M over 4 rounds. Its first funding round was on Dec 16, 2020. Its latest funding round was a Series B round on Feb 04, 2025 for $*****. 9 investors participated in its latest round. Auron Therapeutics has 12 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of Auron Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 04, 2025	2308443	Series B	6437548	8472420	5246981	9501145
Dec 18, 2024	9237385	Series B	4584024	2046511	7204416	8299761
Jul 20, 2022	4207125	Series A	2918602	2583095	Creyon Bio & 4 more	Arkin Holdings & 5 more

Access funding benchmarks and valuations. Sign up today!

View details of Auron Therapeutics's funding rounds and investors

The founders of Auron Therapeutics are Matt Vander Heiden, Eytan Stein, Ross Levine and Kate Yen. Kate Yen is the CEO of Auron Therapeutics.

Here are the details of Auron Therapeutics' key team members:

Matt Vander Heiden: Co-Founder of Auron Therapeutics.
Eytan Stein: Co-Founder of Auron Therapeutics.
Ross Levine: Co-Founder of Auron Therapeutics.
Kate Yen: Co-Founder & CEO of Auron Therapeutics.

View details of Auron Therapeutics's Founder profiles and Board Members

Auron Therapeutics' employee count trend

Auron Therapeutics has 23 employees as of Mar 26. Here is Auron Therapeutics's employee count trend over the years:

Employee count trend for Auron Therapeutics

Uncover Auron Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Auron Therapeutics include Septerna, Philogen and Escient Pharmaceuticals. Here is the list of Top 10 competitors of Auron Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Septerna 2020, San Bruno (United States), Public	Developer of GPCR drug discovery platform for multiple diseases	$250M	RA Capital Management, Third Rock Ventures ... & 14 others	68/100
2nd	Philogen 1996, Sovicille (Italy), Public	Developer of antibody based drugs for angiogenesis-related cancer and inflammatory disorders	$69.7M	The Equity Club, Novacapital & 3 others	68/100
3rd	Escient Pharmaceuticals 2017, San Diego (United States), Acquired	Developer of small molecule based therapeutics for the treatment of inflammatory diseases	$238M	The Column Group, Osage University Partners ... & 12 others	68/100
4th	Protagonist Therapeutics 2001, Milpitas (United States), Public	Developer of oral peptide therapeutics for gastrointestinal diseases	$67M	Lilly Ventures, Canaan & 12 others	67/100
5th	Upstream Bio 2021, Waltham (United States), Public	Developer of therapeutics for allergic and inflammatory diseases	$400M	Venrock, Enavate Sciences & 11 others	66/100
6th	STAR Therapeutics 2018, San Francisco (United States), Series D	Developer of antibody therapies for multiple diseases	$215M	Sofinnova Investments, Viking Global Investors ... & 17 others	66/100
7th	Evommune 2020, Sacramento (United States), Public	Developer of therapeutic options for chronic inflammatory disorders	$276M	Pivotal bioVenture Partners, RA Capital Management ... & 18 others	66/100
8th	MaaT Pharma 2014, Lyon (France), Public	Developer of microbiome therapy for the treatment of intestinal dysbiosis diseases	$42.3M	Symbiosis, Credit Mutuel Equity & 11 others	65/100
9th	Ossium Health 2016, San Francisco (United States), Series C	Developer of cell therapy products for blood cancers, tissue damage healing & radiation poisoning	$125M	Vivo Capital, General Catalyst & 12 others	65/100
10th	CalciMedica 2006, San Diego (United States), Public	Developer of CRAC channel inhibitor drugs for inflammatory diseases	$76.7M	Biogen, SR One & 10 others	64/100
20th	Auron Therapeutics 2018, Wellesley (United States), Series B	Developer of cancer therapeutics for the treatment of blood cancer	$118M	Mubadala, Arkin Holdings & 11 others	62/100